Phase 3 vs Approved — Rare Disease Deal Valuation Comparison

Phase 3 Median Upfront

$971M

Total: $3.4B

Approved Median Upfront

$2.6B

Total: $6.3B

Stage Premium

87%

Approved premium over Phase 3

Phase 3 Royalties

11.2%-20.1%

vs Approved: 16.8%-30%

Model Your Deal

Market Analysis

The Phase 3 to Approved transition in rare disease represents a significant value inflection point. Approved deals carry a median total deal value of $6.3B compared to $3.4B at Phase 3, a 87% premium reflecting clinical de-risking. Upfront payments increase from $971M to $2.6B.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 3 to Approved in rare disease?

Approved rare disease deals command a 87% premium over Phase 3 in total deal value ($6.3B vs $3.4B). Upfronts increase from $971M to $2.6B, reflecting the de-risking value of clinical progression.

How do deal structures differ between Phase 3 and Approved in rare disease?

Phase 3 deals are more milestone-weighted (71% milestones), reflecting higher clinical risk. Approved deals shift toward higher upfront allocations (41% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a rare disease asset?

The optimal licensing window depends on strategic priorities. Phase 3 assets offer lower entry cost for licensees, while Approved assets provide more certainty. The 87% premium from Phase 3 to Approved reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Phase 3 vs Approved — Rare Disease Deal Valuation Comparison

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Phase 3 Rare Disease Deals

Approved Rare Disease Deals

Phase 2 Deal Benchmarks

Ready to Calculate Your Deal Terms?